Characterization of the metastatic melanoma population in Chile that received ipilimumab for the treatment of unresectable or metastatic melanoma

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/32322
• EU PAS number:
  EUPAS6036
• Study ID:
  32322
• Official title and acronym:
  Characterization of the metastatic melanoma population in Chile that received ipilimumab for the treatment of unresectable or metastatic melanoma
• DARWIN EU® study:
  No
• Study countries:
  Chile
• Study description:
  THIS STUDY WAS CANCELED ON DECEMBER 17, 2013 DUE TO LACK OF PI PARTICIPATION.The study will retrospectively collect data from clinical records at all the sites where adult unresectable or MM adult patients treated with at least one dose of ipilimumab therapy in Chile
• Study status:
  Finalised

Research institutions and networks

Institutions

Bristol-Myers Squibb (BMS)

Multiple centres: 15 centres are involved in the study

Study timelines

Date when funding contract was signed

Actual: 01/04/2013

Study start date

Actual: 01/07/2013

Date of final study report

Planned: 30/04/2014

Actual: 17/12/2013

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Bristol-Myers Squibb

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable